JLE

e-VEGF-IMMUNO-actu

MENU

L’angiogenèse existe-t-elle dans les métastases ganglionnaires ? Volume 11, issue 1, Janvier 2016

  • [1] Jeong HS, Jones D, Liao S. Investigation of the lack of angiogenesis in the formation of lymph node metastases. J Nat Cancer Inst. 2015;107:djv155.
  • [2] Allegra CJ, Yothers G, O’Connell MJ. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29:11-6.
  • [3] de Gramont A, Van Cutsem E, Schmoll HJ. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012;13:1225-33.
  • [4] Cameron D, Brown J, Dent R. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomized, phase 3 trial. Lancet Oncol. 2013;14:933-42.
  • [5] Padera TP, Kuo AH, Hoshida T. Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol Cancer Ther. 2008;7:2272-9.
  • [6] Roberts N, Kloos B, Cassella M. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res. 2006;66:2650-7.
  • [7] Matsumoto M, Roufail S, Inder R. Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis. Clin Exp Metastasis. 2013;30:819-32.